While the expanded approval fulfills an unmet meet in postmenopausal women, its benefits are marginal in that population.

The FDA has expanded the approval of Addyi to include the treatment of hypoactive sexual desire disorder in women less than 65 years.

Addyi (flibanserin) was cleared a decade ago to treat low sex drive in women before menopause. A new FDA action allows ...

The FDA expanded the approval of flibanserin (Addyi), a drug that treats low sexual desire in women, to now include some ...

Sprout Pharmaceuticals today announced a monumental milestone for women's health: the U.S. Food and Drug Administration (FDA) ...

Last week, an FDA advisory committee met to discuss the benefits and risks of flibanserin, a drug intended to restore a woman's sexual desire. The panel voted 18-6 that the FDA approve the drug with ...

The manufacturer of a potential “female Viagra” is appealing the Food and Drug Administration's letter denying the drug's approval, saying the company has gone above and beyond what is necessary to ...

Sprout Pharmaceuticals has resubmitted a new drug application to the FDA for flibanserin, an investigational therapy to treat hypoactive sexual desire disorder in women during premenopause, according ...

The US FDA just agreed to back an experimental drug that's being called "female Viagra" and is designed to increase a woman's sexual desire. The FDA panel voted 18-6 in favor of approving the pill, ...

The U.S. Food and Drug Administration's approval of Addyi (flibanserin), a nonhormonal drug to treat low libido in women, has stirred up a great cultural and medical debate on just what defines ...

First things first: Calling female sexual desire drug flinbanserin "viagra for women" is a little misleading. Viagra results in a physical change you can—ahem—see; the little pink pill (like female ...

FDA to consider approving flibanserin to treat women's low sex drive. May 25, 2010 — -- The U.S. Food and Drug Administration may approve a pill next month that could boost women's sex drives.